TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of patients with diagnosis of Acute Coronary Syndrome (ACS) following the care program
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Major adverse cardiac events
Endpoint domain: Adverse events/effects
Primary endpoint: Blood test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PROMIS Fatigue Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: period of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee injury and osteoarthritis outcome pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee injury and osteoarthritis outcome stiffness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee injury and osteoarthritis outcome functional status score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Knee injury and osteoarthritis outcome quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Areas of brain activity from transcutaneous painful stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Areas of brain activity from Capsaicin cream application
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Development of major depressive disorder
Endpoint domain: Mortality/survival
Primary endpoint: Haematological adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in status of uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference on Recurrence Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: reading duration
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Response rate of aflibercept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in lumbar spine bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Peak Macroscopic Conjunctival Hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change percentage of 18F-FES SUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interstitial Volume (ve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exchange Rate (Ktrans)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Varicella Immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: One Year Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Experiencing Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in iPTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmax Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNPs of VDR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25OHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lower extremity injury rates
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients taking an anticoagulant
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: IgG levels in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Measured Concentration of BI 409306 in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of BI 409306 in Plasma From Time 0 to Time of Last Quantifiable Data Point (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of FDOPA PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: D-lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: I-FABP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Endothelin-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: L-lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Satisfaction with OPTIVE PLUS®
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EEG responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Feasibility outcomes for resource assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility outcomes for management assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility outcomes for scientific assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in motor coordination: Jumping Jacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in motor coordination: Finger to Nose Touching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in motor coordination: Single Leg Stance Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of major adverse cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects Who Were Seroprotected for HI Antibodies Against H1N1 Virus Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 2 Strains of Influenza Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acceptability/Satisfaction of Intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Skin Irritation Index
Endpoint domain: Adverse events/effects
Primary endpoint: Positive score on depression measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive score on anxiety measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive score on fatigue measures
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Rate of Adherence to Guideline Prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Serum Concentration-time Curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of short-term POCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Numeric rating scales (NRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritation rate
Endpoint domain: Adverse events/effects
Primary endpoint: AUC(0-Inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IGA-C Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Hamilton Rating Scale for Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: High-sensitivity Troponin T elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptomatic Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall survival (OS) rate 1 year post transplant
Endpoint domain: Mortality/survival
Primary endpoint: Change in sitting blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Off motor daily time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levodopa related Dyskinesia
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained Virologic Response at 12 Weeks (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change from baseline hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute change from baseline fasting glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute change from baseline weighted mean glucose (WMG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent change from baseline fasting triglycerides (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine albumin creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Regression or prevention of progression of precancerous gastric conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in cell proliferation, apoptosis and oncogene expressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection of RNA HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum fetuin A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Frequency of High-Altitude Pulmonary Edema (HAPE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Experiencing an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in 24-hour Urinary Magnesium Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Seated SBP and DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Alignment and Leveling Improvement Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of Betaferon
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Shape Choices in Two Noun Extension Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Number of Words Known Before and After the Interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term Effects of Each Intervention on Language Development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Long-term Effects of Each Intervention on Visual Spatial Skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Long-term Effects of Each Intervention on Working Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total initial cicatrization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Suicidal Ideation and Behaviours Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who discontinue enfuvirtide due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with Serious Adverse Events (SAEs) and Serious AIDS-Defining events
Endpoint domain: Adverse events/effects
Primary endpoint: Healing of diaper dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Blood oxygen level dependent contrast (BOLD-signal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological response during exposure to mental imagery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a ≥8 Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Percent (%) predicted forced expiratory volume at one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in pain monitoring index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of tumor resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of bone formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: UPDRS 3 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global clinical evolution of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Muscle Echogenicity Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal Symptom Rating Scale (GSRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Average Pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: NYHA Classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fatigue Index of knee extensor muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Fatigue
Primary endpoint: Maximum load of effort on cycle ergometer (Balke's protocol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who experienced dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Initial lymphatic flow in inflamed knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial synovitis and its association with lymph flow and node volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial Doppler ultrasound assessment of lymph node size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain/Disability Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: changes in VO2peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence of AF/AT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients with glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lumefantrine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty level by Edmonton frail scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline functional capacity by six minutes walking test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline quality of life by MacNew questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: effective rate of IRE ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Daily Subjective Response From Smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Past 30-day Cigarette Smoking Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Highest Trial Competed for a Menthol Cigarette Puff in the Choice Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of participants with platelet count >= 50000/µL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 7-day point prevalence tobacco abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse-free survival period
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in Urinary Frequency Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: total GSK-3b and phosphorylated (pGSK-3b)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corcordance for Changes in ORi Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trans-lamina cribrosa pressure difference (TLCPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anthropometric changes (BMI, SAT-Topography, waist/hipCF, waist to height ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced Epistaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage unreconciled medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to pleural catheter removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Minimum Observed Plasma Trough Concentration (C trough)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Solicited Injection-Site or Systemic Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of erlotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAD001 Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with HBV DNA below LOD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Skin Flora Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PAC-SYM Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PAC-QOL Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to the First Adjudicated Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Attachment Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awareness of the importance to maintain good oral health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discriminating power of VOCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axillary lymph node metastasis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Mean Change in Oral Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in metabolic profile of blood serum metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of biological samples negative/positive for opioid agonists
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of use or abstinence from opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Oxido-sensitive index level in spermatozoa and seminal plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fractional intestinal calcium absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence and intensity of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: time to onset of pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to remedication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number and percentage of patients who prematurely discontinue from the study due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Post operative pain level on numerical pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative pain level on visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proliferative diabetic retinopathy progression/regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: neonatal morbidity composite measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving ACR 20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Positive Anti-abatacept or Anti-CTLA4-T Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of NRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biceps brachii muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hormones in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Virologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of successful fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Count of Adverse Events Reported
Endpoint domain: Adverse events/effects
Primary endpoint: ischemia reperfusion injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Urgency Urinary Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes